E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064848 |
E.1.2 | Term | Chronic kidney disease |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Patients with reduced kidney function (kidney disease) have high rates of hardening of the blood vessels, which leads to early heart disease and strokes. Previous research has shown that using low dosage of a 'water tablet', spironolactone in patients with early kidney disease in a hospital outpatient setting improved heart structure and function as well as reduced blood vessel stiffness.
STOP-CKD study aims to determine if blood vessel stiffness can be safely reduced with the use of low dose spironolactine in people with early stage kidney disease managed at general practices. |
|
E.2.2 | Secondary objectives of the trial |
The study also aims to examine: 1. Rate of side effects and safety of the use of spironolactone in people with early stage kidney disease. 2. Patients' and health care professionals’ views to kidney disease, the use of spironolactone in people with early stage kidney disease in a primary care setting as well as their views to research study in the primary care. 3. Recruitment rate of participants to the study.
In addition to addressing the above questions, this pilot study (small scale preliminary study) is to test the feasibility of a full-scale definitive study to determine whether cardiovascular events might be safely be reduced with the use of spironolactone in addition to standard management of early stage kidney disease in primary care setting.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age over 18 years 2. Diagnosis of CKD Stage 3 (eGFR 30-59 ml/min/1.73m2) using the MDRD (Modification of Diet in Renal Disease) equation.
|
|
E.4 | Principal exclusion criteria |
•Diabetes Mellitus •Terminal disease or felt otherwise unsuitable by their general practitioner (GP) •Chronic heart failure i.e. a clinical diagnosis or known ejection fraction (EF) <55% •Atrial fibrillation •Alcohol or drug abuse •Inability to comply with trial medication and follow-up •Documented previous hyperkalaemia or intolerance of spironolactone •Documented Addison’s disease and/or on fludrocortisone •Severe hypertension: blood pressure ≥ 180/110 mmHg •Systolic blood pressure less than 120mmHg •Recent acute kidney injury or hospital admission (within past 6 weeks) •Chronic diarrhoea •Pregnancy •ACR>70 mg/mmol (will require specialist referral if not already made) •Serum potassium ≥ 5 mmol/L on screening blood test •Concomitant co-trimoxazole medication •Concomitant angiotensin-converting enzyme inhibitor AND angiotensin II receptor blocker medication |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure for the study is the change of pulse wave velocity (measurement of arterial stiffness). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Baseline (at commencement of trial medication) 2. At week 40 (40 weeks after commencement of trial medication). Trial medication will be stopped at week 40. 3. At 46 week (6 weeks after stopping the trial medication) |
|
E.5.2 | Secondary end point(s) |
The secondary end points are: •Change in blood pressure •Change in estimated Glomerular Filtration Rate (eGFR) •Change in urinary albumin to creatinine ratio (ACR) •Change of pulse wave characteristics •Incidence of hyperkalaemia •Incidence of hypotension (<100mmHg or >20mmHg systolic drop on standing) •Incidence of side-effects •Incidence of other adverse events or adverse reaction defined by the Medicines and Healthcare products Regulatory Agency (MHRA) •Health status as measured by EQ5D
Subgroup study will also examine: •Difference in serum potassium reading using two different methods of transport and analysis •Qualitative data outcome on patients’ and primary care physicians’ attitudes towards spironolactone in CKD in community setting and the potential barriers exist to its use. •Qualitative data outcome on patients’ attitudes to CKD and research in CKD in a community setting and the potential barriers exist for participation.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The timepoints of evaluation of all these end points are at baseline, week 40 and week 46. There will also be continuous evaluation of the incidence of hyperkalaemic, hypotension, side effection of trial medication and other adverse events or reactions throughtout the study period.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |